Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 47

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 3
Chunk 47
---
 of operations and could affect the reporting of transactions
already completed before the announcement of a change. The adoption of new or revised accounting principles may require it to make changes
to its systems, processes and control, which could have a significant effect on its reported financial results, cause unexpected financial
reporting fluctuations, retroactively affect previously reported results or require it to make costly changes to its operational processes
and accounting systems upon or following the adoption of these standards.

If NewGenIvf’s estimates or judgments
relating to its critical accounting policies prove to be incorrect, its results of operations could be adversely affected.

The preparation of financial
statements in conformity with U. S. GAAP requires management to make estimates and assumptions that affect the amounts reported in
NewGenIvf’s consolidated financial statements and accompanying notes appearing elsewhere in this prospectus. NewGenIvf bases its
estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, as provided
in the section titled “ Management’s Discussion and Analysis of Financial Condition and Results of Operations of NewGenIvf - Critical
Accounting Policies, Judgments and Estimates.” The results of these estimates form the basis for making judgments about the
carrying values of assets, liabilities and equity, and the amount of revenue and expenses that are not readily apparent from other sources.
NewGenIvf’s results of operations may be adversely affected if its assumptions change or if actual circumstances differ from those
in its assumptions, which could cause its results of operations to fall below the expectations of securities analysts and investors, resulting
in a decline in the market price of its Class A Ordinary Shares and Warrants.

NewGenIvf is subject to anti-corruption,
anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject it to criminal or civil liability
and harm its business, financial condition and results of operations.

NewGenIvf is subject to anti-corruption,
anti-bribery, anti-money laundering and similar laws in the jurisdictions where we have subsidiary operations. In Thailand, the Anti-Money
Laundering Act B. E. 2542 (1999), the Act Supplementing the Constitution Relating to the Prevention and Suppression of Corruption
B. E. 2561 (2018) of Thailand, and the Penal Code of Thailand, domestic bribery laws, and other anticorruption and anti-money laundering
laws in the countries in which it conducts activities. Anti-corruption and